Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
European Organisation for Research and Treatment of Cancer · North Estonia Medical Centre · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
733
total citations
- FWCI
- 70.51
- Percentile
- 100%
- References
- 28
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Internal medicine
- Lung cancer
- Population
- Interim analysis
- Oncology
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.